Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies
The DOI matches its Crossref record; 154 of the 161 references it cites were found in a registry or an index.
Abstract
BACKGROUND Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs) versus oral antipsychotics for schizophrenia has been inconsistent across study designs. The aim of this study was to evaluate the comparative benefits of LAIs versus oral antipsychotics in three study designs to inform clinical decision making. METHODS We did a comprehensive systematic review and meta-analysis comparing LAIs versus oral antipsychotics for schizophrenia covering three study designs: randomised controlled trials (RCTs), cohort studies, and pre-post studies. Our literature search was without language restrictions, in MEDLINE and PubMed, the Cochrane Library, Scopus, and Embase, for studies published from database inception up to a last search on March 13, 2020. We also searched for unpublished studies and ClinicalTrials.gov. We included studies lasting at least 6 months that targeted adults with schizophrenia and related disorders (>80% of participants). Studies on penfluridol (neither an LAI or daily oral antipsychotic), case reports, and case series with fewer than 20 patients were excluded. Two investigators independently extracted study-level data and resolved disagreement by consensus, or via a third investigator. Study authors were contacted to obtain additional information as needed. For our primary outcome we meta-analysed the risk ratio (RR) for hospitalisation or relapse with LAIs versus oral antipsychotics by a random-effects model, with hospitalisation used p…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2014) · Medical Entomology and Zoology · Cited by 17,633
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationLeucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Research works printed but not linked: 6
- Kamijima, 2009, Comparison study between risperidone long-acting injectable and risperidone tablets in patients with schizophrenia, Jpn J Clin Psychopharmacol, 12, 1199
- Kaneno, 1991, A double-blind comparison study on the efficacy and safety of fluphenazine decanoate (SQ10,733) and oral haloperidol in the treatment of schizophrenic patients, Clin Eval, 19, 15
- Li, 1996, The effect of haloperidol decanoate on negative and positive symptoms of schizophrenia, Chinese Journal of Nervous and Mental Diseases, 22, 9
- Potapov, 2008, Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine, Int J Neuropsychopharmacol, 11, 158
- Bellido, 2008, Depot antipsychotics in outpatients with schizophrenia improved compliance and reduced the incidence of relapses, Methods Find Exp Clin Pharmacol, 30, 137
- Calabresi, 1983, The long-term pharmacological treatment of schizophrenic patients: comparing effects resulting from daily administered neuroleptics and “long acting”, Riv Sper Freniatr Med Leg Alien Ment, 107, 1205
Cited by
Schneider-Thoma, J., Chalkou, K., Dörries, C., Bighelli, I., Ceraso, A., Huhn, M., Siafis, S., Davis, J. M., Cipriani, A., Furukawa, T. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01997-8 · Cited by 224
Schneider‐Thoma, J., Chalkou, K., Doerries, C., Bighelli, I., Ceraso, A., Huhn, M., Siafis, S., Davis, J. M., Cipriani, A., Furukawa, T. A., et al. (2022) · doi:10.48350/166230 · Cited by 180
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gaebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 179
Self-citationCorrell, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 182
Self-citationEuropean Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Vita, A., Gäebel, W., Mucci, A., Sachs, G., Barlati, S., Giordano, G. M., Nibbio, G., Nordentoft, M., Wykes, T., & Galderisi, S. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2315 · Cited by 175
“A recent and well-conducted meta-analysis [63] compared oral and long-acting injectable formulations of antipsychotics on a wide range of outcomes (efficacy, effectiveness, hospitalizations, adverse events, cognition, functioning, and quality of life) and included 137 studies (randomized controlled trials, cohort stud…”
Background
Metadata
- Authors
- Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U.
- Affiliations
- Northwell Health (US)
- Sumitomo Dainippon Pharma (Japan) (JP)
- Keio University (JP)
- Corresponding author
- Kishimoto, Taishiro
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 8
- Issue
- 5
- Pages
- 387-404
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W3154038235
- Semantic Scholar
- ddfa11f6eb160b93cadf592656080c27d0ceb132
- Cited by
- 369
- References
- 161
- Citations by year
- 2026: 69 · 2025: 68 · 2024: 72 · 2023: 74 · 2022: 64 · 2021: 22
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Takeda Pharmaceutical Company
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
- Keywords
- long-acting injectable antipsychotics, oral antipsychotics, schizophrenia, maintenance therapy, relapse, hospitalization, study design comparison, cohort studies, before-after study, antipsychotic efficacy and safety, quality of life, cognitive function, medication adherence, relapse prevention, antipsychotic switching
- MeSH terms
- Administration, Oral, Delayed-Action Preparations, Humans, Injections, Schizophrenia, Antipsychotic Agents, Cohort Studies, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. https://app.cochat.ai/papers/10.1016/s2215-0366(21)00039-0
- The paper
- Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(21)00039-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.